Sreenath Nampally

Researchers at the NIH, led by Dr. Thomas Bugge and Dr. Stephen Leppla have engineered components of the toxin from the bacteria responsible for Anthrax to be specifically activated by two proteases enriched in tumors – urokinase Plamingen Activator (uPA) and Matrix Metalloproteases (MMPs).

As part of the feasibility study, we conducted
- Intellectual Property Analysis to assess Freedom To Operate
- Strategic Market Research & Analysis
- Legal and Regulatory Analysis
-… Show more

Researchers at the NIH, led by Dr. Thomas Bugge and Dr. Stephen Leppla have engineered components of the toxin from the bacteria responsible for Anthrax to be specifically activated by two proteases enriched in tumors – urokinase Plamingen Activator (uPA) and Matrix Metalloproteases (MMPs).

As part of the feasibility study, we conducted
- Intellectual Property Analysis to assess Freedom To Operate
- Strategic Market Research & Analysis
- Legal and Regulatory Analysis
- Competitive Analysis
- Business Model Analysis including pricing and revenue forecast
- Recommendations to NIH's Office of Tech Transfer (OTT) Show less

Conducted feasibility analysis for a new invention within the pharmaceutical biotechnology market.
1. Worked with inventors to understand technology, commercial embodiments, current stage of development, and unresolved technical and scientific questions
2. Developed value proposition to clarify the unmet medical need the invention addressed
3. Intellectual Property: Assessment of Novelty and Freedom to Operate
a. Conducted a prior art and novelty search (USPTO, Lexis, Derwent… Show more

Conducted feasibility analysis for a new invention within the pharmaceutical biotechnology market.
1. Worked with inventors to understand technology, commercial embodiments, current stage of development, and unresolved technical and scientific questions
2. Developed value proposition to clarify the unmet medical need the invention addressed
3. Intellectual Property: Assessment of Novelty and Freedom to Operate
a. Conducted a prior art and novelty search (USPTO, Lexis, Derwent, Google Patents, WIPO, SIPO)
b. Determined how the intellectual property is currently protected (patents, trademarks, copyrights, trade secrets, and proprietary know-how)
c. Reviewed the scientific literature
d. Assessed the patent landscape and Freedom to Operate
4. Strategic Market Analysis
a. Stakeholder analysis
b. Global operating environment of the technology sector and maturity of the market
c. Value Chain Analysis
d. Quantitative and qualitative research into demand
i. Customer Wants and Needs (interviews, surveys, focus groups, blogs, forums)
ii. Desired product attributes (cost, performance, benefits, features)
e. Competitive Analysis
f. Market Sizing
i. Target Market Analysis
g. Identify Legal and Regulatory Issues including non-market forces
5. Created a Business Model
a. Recommended reimbursement strategy
b. Assessed the likely pathway to market and monetization of the intellectual property asset (e.g. license, joint venture, spin-out, sale)
c. Identified commercialization milestones that must be achieved to go to market
d. Created Financial Plan with projected volume of sales over next 20 years; projected net revenue over next 5 years; cost of goods sold; pricing (licensing fee, royalties); Operating expenses
e. Attracted potential funding sources for the immediate next steps and later stage
f. Developed exit strategy
6. Provided Preliminary Recommendation on Go, No-Go, actions necessary to reach a Go state
Show less

HealthWatch is a social enterprise that fights the rising epidemic of dengue fever in India by providing state-of-the-art mobile diagnosis and monitoring blood tests.

Insumi is conceived as a web-based business-related social platform that will primarily combine task management and meeting coordination. As part of the feasibility study, we conducted
- Micro and Macro Level Market Analysis
- Macro Level Industry Analysis (Five Forces Analysis)
- Financial Projections
- Revenue Forecast by Concept Purchase Intent and Chain Ratio Methods
- Break Even Analysis
- Operating Cash Cycle Characteristics